Longevity Breakthrough: Longeveron Publishes Phase 2b Trial Data Proving MSC Therapy Reverses Age-Related Frailty
【Abstract】: (Clinical Trial Milestone) On February 25, 2026, Longeveron Inc. published its highly anticipated Phase 2b clinical trial results in the prestigious journal Cell Stem Cell. The study proved that intravenous laromestrocel, a human bone marrow-derived allogeneic mesenchymal stem cell (MSC) product, significantly improved the physical functioning and overall condition of patients suffering from age-related clinical frailty after nine months, compared to a placebo.
Business Insight: This officially validates MSCs as a premier, scalable treatment for systemic aging and chronic inflammation. Clinics and medical tourism facilitators exhibiting at CMTF can now confidently market allogeneic MSC therapies as evidence-based "healthspan" extenders. This shifts the longevity market away from unproven preventative supplements toward targeted, FDA-track cellular therapeutics.
【Keywords】: #CellTherapy #StemCells #LongevityMedicine
【Source Link】: Markets Insider / Cell Stem Cell Publication (Feb 25, 2026)
